The stock of Altimmune Inc. (NASDAQ:ALT) last traded at $3.39, up 2.11% from the previous session.
Data from the available sources indicates that Altimmune Inc. (NASDAQ:ALT) is covered by 8 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $50.00 and a low of $6.00, we find $22.50. Given the previous closing price of $3.32, this indicates a potential upside of 577.71 percent. ALT stock price is now -19.01% away from the 50-day moving average and -62.78% away from the 200-day moving average. The market capitalization of the company currently stands at $170.62M.
In total, 1 analysts have assigned it a hold rating, and 7 have given it a buy rating. Brokers who have rated the stock have averaged $24.38 as their price target over the next twelve months.
With the price target reduced from $20 to $6, Goldman Downgraded its rating from Buy to Neutral for Altimmune Inc. (NASDAQ: ALT).
In other news, Eisenstadt Richard I, Chief Financial Officer bought 10,000 shares of the company’s stock on Mar 24. The stock was bought for $43,140 at an average price of $4.31. Upon completion of the transaction, the Chief Financial Officer now directly owns 22,010 shares in the company, valued at $74613.9. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 23, Chief Medical Officer Harris Matthew Scott bought 10,000 shares of the business’s stock. A total of $42,200 was incurred on buying the stock at an average price of $4.22. This leaves the insider owning 33,311 shares of the company worth $0.11 million. Insiders disposed of 95,241 shares of company stock worth roughly $0.32 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ALT stock. A new stake in Altimmune Inc. shares was purchased by OCCUDO QUANTITATIVE STRATEGIES LP during the first quarter worth $1,471,000. JUMP FINANCIAL, LLC invested $979,000 in shares of ALT during the first quarter. In the first quarter, SCHONFELD STRATEGIC ADVISORS LLC acquired a new stake in Altimmune Inc. valued at approximately $930,000. SQUAREPOINT OPS LLC acquired a new stake in ALT for approximately $726,000. HRT FINANCIAL LP purchased a new stake in ALT valued at around $559,000 in the second quarter. In total, there are 177 active investors with 94.70% ownership of the company’s stock.
With an opening price of $3.3700 on Thursday morning, Altimmune Inc. (NASDAQ: ALT) set off the trading day. During the past 12 months, Altimmune Inc. has had a low of $3.20 and a high of $23.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 11.60, and a quick ratio of 11.60. The fifty day moving average price for ALT is $4.1550 and a two-hundred day moving average price translates $9.0641 for the stock.
The latest earnings results from Altimmune Inc. (NASDAQ: ALT) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.4, beating analysts’ expectations of -$0.48 by 0.08. This compares to -$0.44 EPS in the same period last year. The company reported revenue of $21000.0 for the quarter, compared to $32000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -34.38 percent.
Moreover, the firm recently paid out its quarterly dividend on 02/03/2017. Investors who held shares on 01/24/2017 were paid a $2.91 dividend.
Altimmune Inc.(ALT) Company Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
